Literature DB >> 19060605

Management of chronic pain in cancer survivors.

Michael H Levy1, Marcin Chwistek, Rohtesh S Mehta.   

Abstract

Chronic pain is a frequent complication of cancer and its treatments and is often underreported, underdiagnosed, and undertreated. Pain in cancer survivors is caused by residual tissue damage from the cancer and/or the cancer therapy. This pain can be divided into 3 pathophysiologic categories: somatic, visceral, and neuropathic. The most common treatment-induced chronic pain syndromes are neuropathies secondary to surgery, radiation therapy, and chemotherapy. Comfort and function are optimized in cancer survivors by a multidisciplinary approach using an individually tailored combination of opioids, coanalgesics, physical therapy, interventional procedures, psychosocial interventions, and complementary and alternative modalities. Management of chronic pain must be integrated into comprehensive cancer care so that cancer patients can fully enjoy their survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060605     DOI: 10.1097/PPO.0b013e31818f5aa7

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  28 in total

1.  The Italian response to cancer survivorship research and practice: developing an evidence base for reform.

Authors:  Vittorio Mattioli; Rosanna Montanaro; Francesca Romito
Journal:  J Cancer Surviv       Date:  2010-07-21       Impact factor: 4.442

2.  The need for a Canadian pain strategy.

Authors:  Mary E Lynch
Journal:  Pain Res Manag       Date:  2011 Mar-Apr       Impact factor: 3.037

3.  What Is the Latest in Pain Mechanisms and Management?

Authors:  Mary E Lynch
Journal:  Can J Psychiatry       Date:  2015-04       Impact factor: 4.356

4.  Frequency, characteristics, and correlates of pain in a pilot study of colorectal cancer survivors 1-10 years post-treatment.

Authors:  Amy E Lowery; Tatiana Starr; Lara K Dhingra; Lauren Rogak; Julie R Hamrick-Price; Maria Farberov; Kenneth L Kirsh; Leonard B Saltz; William S Breitbart; Steven D Passik
Journal:  Pain Med       Date:  2013-09-06       Impact factor: 3.750

5.  Long-Term Opioid Therapy in Older Cancer Survivors: A Retrospective Cohort Study.

Authors:  Rahul Shah; Lin-Na Chou; Yong-Fang Kuo; Mukaila A Raji
Journal:  J Am Geriatr Soc       Date:  2019-04-26       Impact factor: 5.562

6.  Chronic neuropathic pain negatively associated with employment retention of cancer survivors: evidence from a national French survey.

Authors:  Caroline Alleaume; Marc-Karim Bendiane; Anne-Déborah Bouhnik; Dominique Rey; Sébastien Cortaredona; Valérie Seror; Patrick Peretti-Watel
Journal:  J Cancer Surviv       Date:  2017-10-04       Impact factor: 4.442

7.  Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health.

Authors:  Ana Mańas; Juan Pablo Ciria; María Carmen Fernández; María Luisa Gonzálvez; Virginia Morillo; María Pérez; Xavier Masramon; Vanessa López-Gómez
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

8.  Pain in long-term breast cancer survivors: frequency, severity, and impact.

Authors:  Mark P Jensen; Hao-Yuan Chang; Yeur-Hur Lai; Karen L Syrjala; Jesse R Fann; Julie R Gralow
Journal:  Pain Med       Date:  2010-06-08       Impact factor: 3.750

9.  A survey of perceptions, attitudes, knowledge and practices of medical oncologists about cancer pain management in Spain.

Authors:  Jesús García-Mata; Cecilio Álamo; Javier de Castro; Jorge Contreras; Rafael Gálvez; Carlos Jara; Antonio Llombart; Concepción Pérez; Pedro Sánchez; Susana Traseira; Juan-Jesús Cruz
Journal:  Clin Transl Oncol       Date:  2018-05-02       Impact factor: 3.405

10.  Effect of histone deacetylase inhibitor JNJ-26481585 in pain.

Authors:  Kathryn E Capasso; Melissa T Manners; Rehman A Quershi; Yuzhen Tian; Ruby Gao; Huijuan Hu; James E Barrett; Ahmet Sacan; Seena K Ajit
Journal:  J Mol Neurosci       Date:  2014-08-02       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.